produces hyperglycemia and increases whole body glucose uptake. The purpose of the present study was to determine in rats which tissues are responsible for the elevated rate of glucose disposal. NMDA was injected intracerebroventricularly, and the glucose metabolic rate (R,) was determined for individual tissues 20-60 min later using 2-deoxy-D-[U-14C]glucose.
NMDA decreased R, in skin, ileum, lung, and liver (30-35%) compared with time-matched control animals. In contrast, R, in skeletal muscle and heart was increased X0-160%.
This increased R, was not due to an elevation in plasma insulin concentrations.
In subsequent studies, the sciatic nerve in one leg was cut 4 h before injection of NMDA. NMDA increased R, in the gastrocnemius (149%) and soleus (220%) in the innervated leg. However, R, was not increased after NMDA in contralateral muscles from the denervated limb. Data from a third series of experiments indicated that the NMDA-induced increase in R, by innervated muscle and its abolition in the denervated muscle were not due to changes in muscle blood flow. The results of the present study indicate that 1) central administration of NMDA increases whole body glucose uptake by preferentially stimulating glucose uptake by skeletal muscle, and 2) the enhanced glucose uptake by muscle is neurally mediated and independent of changes in either the plasma insulin concentration or regional blood flow. denervation; excitatory amino acid; non-insulin-mediated glucose uptake; 2-deoxyglucose; glutamate; blood flow; rat INTRACEREBROVENTRICULAR injectionofeitherkainateor N-methyl-D-aspartate (NMDA) produces a rapid and sustained increase in whole body glucose turnover (16). Regardless of which excitatory amino acid (EAA) agonist was used, elevations in the rate of both hepatic glucose production and peripheral glucose utilization were observed. These changes in carbohydrate metabolism were associated with increased circulating levels of various stress hormones, including catecholamines, glucagon, and corticosterone, and a reduction in plasma insulin concentrations (16). Previous studies have further characterized the mechanism responsible for the EAAinduced changes in glucose production by the liver (16). However, the specific tissues and mechanism responsible for the enhanced rate of glucose disposal have not been elucidated.
Glucose uptake by peripheral tissues can occur by either of two mechanisms (7). The first mechanism, termed insulin-mediated glucose uptake (IMGU), occurs exclusively in insulin-sensitive tissues, such as muscle and adipose tissue (13). The second mechanism, termed non-insulin-mediated glucose uptake (NIMGU), occurs in both insulin-sensitive and insulin-nonsensitive tissues (1, 12) . Under basal postabsorptive conditions, in a number of species, NIMGU appears to account for N 7046% of the total whole body glucose uptake (1, 2, 12) . Most commonly, an increase in NIMGU occurs during conditions in which hyperglycemia is present (e.g., diabetes mellitus), in which glucose transport is enhanced by mass action (2, 10). However, NIMGU is also stimulated during euglycemic conditions in which the avidity of tissues for glucose is increased (e.g., infection, cold exposure, and exercise) (12, 17, 20) . Because the central administration of NMDA alters plasma levels of both insulin and glucose, glucose uptake by peripheral tissues may be influenced by both insulinand non-insulin-mediated mechanisms.
The purpose of the present study was to determine which tissues are responsible for the increased whole body glucose disposal observed in rats injected intracerebroventricularly with NMDA. On the basis of results from the initial experiments, additional experiments were performed to determine whether the NMDAinduced change in glucose uptake by skeletal muscle was abolished by local denervation and whether alterations in glucose uptake could be explained by changes in organ blood flow.
MATERIALS AND METHODS
Animal preparation. Male Sprague-Dawley rats (350-375 g; Charles River, Wilmington, MA) were used in all experiments. Animals were anesthetized with an intraperitoneal injection of ketamine and xylazine (90 mg/kg and 9 mg/kg, respectively) and positioned in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA). A cannula was inserted unilaterally into the lateral ventricle of the brain, as previously described (11, 16). After surgery, animals were placed in individual cages, provided with food and water ad libitum, and allowed to recover for 4-5 days. of the neutral extract and the radioactivity remaining after the Somogyi treatment (10, 12, 13). The glucose metabolic rate (Rg; nmol l min-l l g wet wt-l> for each tissue examined was calculated on the basis of in vivo accumulation of phosphorylated 2-[U-14C]DG by a respective tissue, the integrated 2-[W4C]DGto-glucose ratio in plasma during the 40-min labeling period, and the lumped constant (12, 13). Organ glucose utilization rates were calculated as the product of organ weight (g/100 g body weight) and tissue R, values (nmol min-l l g tissue-l) (12, 13). The peripheral glucose utilization rate was calculated as the algebraic sum of the individual rates for all of the soft tissues examined.
Arterial blood samples for the determination of plasma hormone levels were collected in chilled syringes containing aprotinin (500 KIU/ml), and plasma was stored at -70°C until assayed. Immunoreactive insulin, glucagon, and corticosterone were measured by radioimmunoassay (DPC, Los Angeles, CA).
A second series of experiments was performed to determine whether the changes in glucose uptake by skeletal muscle were dependent on the muscle being innervated.
These rats were surgically prepared as described above. In addition, on the morning of each experiment, rats were lightly anesthetized with ether, and a 5-mm section of the sciatic nerve was removed unilaterally.
On the contralateral control leg, an incision was made and the nerve was visualized but not cut. Animals were conscious and moving in their cages 5-10 min after the denervation procedure was completed. All experiments were performed 4 h after denervation.
Cardiac output (CO) and regional blood flow determinations. In this experimental series, each animal had a catheter implanted in the left ventricle via the right carotid artery. The position of the catheter tip was demonstrated by the left ventricular pressure pulse, and its location in the ventricle was verified by postmortem examination.
A catheter was also placed in the caudal artery of the tail. After an overnight fast, a unilateral sciatic nerve transection was performed on each rat. Thirty minutes after intracerebroventricular injection of NMDA, microspheres labeled with 141Ce (15 pm in diameter; DuPont-New England Nuclear, Boston, MA) were injected into the left ventricle for determination of CO and regional blood flow (12). The microspheres were slowly injected into the left ventricle, and the catheter was flushed with sterile saline. A reference blood sample was withdrawn from the caudal artery over a 1-min period at a constant rate of 0.34 ml/min. At the conclusion of each experiment, rats were anesthetized with pentobarbital and exsanguinated. Tissues were excised, weighed, and counted for radioactivity (model 1272, LKB,
RESULTS
Regional glucose uptake. The intracerebroventricular injection of NMDA resulted in a mild hyperglycemia (+ 29%, Table 1 ). It also increased plasma corticosterone levels (93%) but did not significantly alter circulating concentrations of either insulin or glucagon (Table 1) . These changes are consistent with those previously reported (16). The calculated rate of total peripheral glucose disposal in control rats, based on the 2-DG uptake values for individual tissues, was 4.47 t 0.36 ~mol*minl l 100 g body wt-l in control rats. This value was increased 41% in rats injected intracerebroventricularly with NMDA (6.28 t 0.38 kmol l min-'0 100 g body wt-l; P < 0.05). H owever, this increase in whole body glucose uptake was not distributed evenly among the various tissues in the body. A sample of hindlimb skeletal muscle, which is a mixture of red and white fiber types, and heart demonstrated a 150-160% increase in R, (Fig. 1) . In contrast, R, in skin, ileum, lung, and liver actually decreased 30-35% when determined 20-60 min after intracerebroventricular injection of NMDA (Fig. 2) . Inthe th t o er issues examined, including kidney, epididymal fat, diaphragm, spleen, and whole brain, NMDA did not significantly alter tissue R, (Fig. 3) . In both control and NMDA-treated rats, R, in muscle, intestine, and skin accounted for -90% of the total whole body glucose disposal. As a result of the central injection of NMDA, however, there was a redistribution of glucose uptake, away from the intestine and skin and toward skeletal muscle (Fig. 4) . After NMDA administration, glucose uptake by skeletal muscle alone was estimated to account for almost 70% of the rate of glucose disposal by the whole animal. Neural control of muscle glucose uptake. In separate experiments the importance of innervation to the enhanced glucose uptake in skeletal muscle was examined. In these experiments, cutting the sciatic nerve eliminates neural input to the muscles of the lower hindlimb; however, the adductor longus muscle, which was also examined, lies proximal to the point of denervation and hence remains innervated.
In control rats, denervation did not alter R, of the gastrocnemius, soleus, or adductor longus compared with the innervated muscles from the contralateral leg of the same animal (Fig. 5) . Central injection of NMDA increased R, in the innervated gastrocnemius (149%), soleus (220%), and adductor longus (24%). In contrast, no increase in R, was observed in the gastrocnemius and soleus muscles after denervation.
The increased R, in the adductor longus was the same in both legs. 
Hemodynamics
and regional blood flow. NMDA produced minimal changes in hemodynamics when determined 30 min after intracerebroventricular injection (Table 2) . No h c anges in MABP, cardiac index, SV, or TPR were detected in NMDA-treated rats compared with time-matched control animals. NMDA-treated rats did demonstrate a 15% elevation in HR. Although NMDA did not significantly alter cardiac index, it did substantially influence regional blood flow. Table 3 illustrates that NMDA increased blood flow to the small intestine (89%), cecum (141%), spleen (32%), and adrenal gland (56%). As a result of these changes, the calculated hepatic portal blood flow was elevated 70% compared with control values (Fig. 6B) . NMDA also produced a dramatic threefold elevation in hepatic arterial blood flow (Fig. 6A) . Collectively, these changes more than doubled the total hepatic blood flow (Fig. 6 C) . Two of the tissues examined, epididymal fat and lung, demonstrated a significant reduction in blood flow after injection of NMDA (32 and 45%, respectively; Table 3 ). Blood flow to the other tissues examined (including skin, pancreas, stomach, colon, kidney, heart, diaphragm, and whole brain) was not altered 30 min after the intracerebroventricular injection of NMDA. Blood flow was also determined in animals after unilateral sectioning of the sciatic nerve. In both control and NMDA-treated rats, blood flow to the denervated gastrocnemius and soleus muscle was reduced (Fig 7) . However, NMDA did not significantly alter blood flow to the gastrocnemius, soleus, or adductor longus regard- less of whether the muscle was innervated or denervated (Fig. 7) .
Intravenous injection of NMDA. In separate animals, NMDA was injected intravenously at the same dose as that administered intracerebroventricularly (6 nmol). This low dose of NMDA did not result in detectable changes in either regional glucose uptake or blood flow in the tissues examined (data not shown).
DISCUSSION
The NMDA-induced hyperglycemia, although relatively mild, would be expected to increase glucose uptake in most tissues as a result of mass action (1, 2, 10, 12, 13). In contrast, the mild insulinopenia produced by NMDA would tend to impair glucose uptake by insulinsensitive tissues, such as muscle and adipose tissue (12, 13). The present study indicates that central administration of NMDA profoundly alters regional glucose uptake in an unexpected manner. Despite the hyperglycemia, glucose uptake by several tissues (skin, ileum, lung, and liver) was reduced in NMDA-treated rats. It seems unlikely that the small decrease in insulin concentration was the cause for this reduction, because an impairment of glucose uptake by these particular tissues was not demonstrated in other studies in which a more severe insulinopenia was produced by somatostatin (10, 12). Furthermore, an alteration in blood flow to these tissues appears to be an unlikely causative factor. Under basal postabsorptive conditions, glucose uptake by these tissues occurs almost exclusively by non-insulin-mediated mechanisms (10,12,13). Whereas several conditions are known to increase NIMGU (12, 17, 20) , there is no information available concerning mechanisms that decrease NIMGU. Studies by Baron and associates (3, 4) have shown, however, that although the stress hormones epinephrine, glucagon, and cortisol are capable of impairing IMGU, they apparently do not downregulate NIMGU in a similar manner. Values are means t SE; n = 7 rats/group.
Hepatic portal values were estimated from sum of arterial inflow to pancreas, stomach, spleen, small intestine, cecum, and large intestine.
Total hepatic blood flow values were calculated as sum of hepatic portal and arterial flows. *P < 0.05 vs. time-matched control values.
Glucose uptake by skeletal muscle and heart was selectively enhanced by NMDA. Although hyperglycemia may account for a small part of the increased NIMGU, it was not of sufficient magnitude to explain the majority of the enhanced glucose uptake by muscle (l&13). The increased glucose uptake in skeletal muscle was clearly dependent on neural innervation, because acute denervation before NMDA prevented the stimulation of glucose uptake by the gastrocnemius and soleus. Ablation of the NMDA-induced increase in glucose uptake could not be explained by changes in regional blood flow in the denervated muscles. From these data, it is not possible to determine whether denervation influenced the NMDA-induced increase in glucose uptake by altering nerve activity to the muscle and/or muscle responsiveness to a nonneural stimulus. The latter possibility is known to occur and is exemplified by the development of insulin resistance in denervated muscle (25). Whether denervation also impairs NIMGU has not been investigated. Regardless of the exact mechanism, intracerebroventricular injection of NMDA altered regional glucose disposal, resulting in a redistribution of glucose toward skeletal muscle and away from skin and intestine (and, to a lesser extent, other tissues). This redistribution is similar to that seen after intracerebroventricular injection of the cholinergic agonist carbachol (11) but unlike that observed in other stress conditions produced by diabetes, infection, or endotoxemia (10,12,13,15).
An increase in glucose uptake by skeletal muscle and heart has been observed after electrical or chemical stimulation of the ventral medial hypothalamus (VMH) (21,22) and in the heart after stimulation of efferent cardiopulmonary nerves (24). It is important to note that the study by Sudo et al. (22) was performed in anesthetized animals, a procedure that eliminates or minimizes muscle contractile activity. Hence, these data suggest that, although the present study was performed in conscious animals, a change in muscle activity induced by NMDA was not the cause of the increased glucose uptake in skeletal muscle. The same study by Sudo et al. also demonstrated that VMH stimulation increased glucose uptake in brown adipose tissue and that the increase was prevented by prior denervation. This increased glucose uptake appears to be due to an increase in the functional activity of the membranebound glucose transporters and not to changes in either the number or affinity of those transporters (23). These findings are in contrast to those observed after insulin treatment, in which the number of membrane-bound transporters is increased (8, 23), and further illustrate that VMH stimulation and insulin enhance glucose transport by different mechanisms. Although NMDAtype receptors are present throughout the brain, the VMH has the highest regional density of such receptors within the hypothalamus (14). Therefore it is possible that NMDA injected into the lateral ventricle exerted its effect by interacting with receptors located in the VMH.
Although regional blood flow measurements were performed primarily to determine whether NMDA and/or denervation altered blood flow to skeletal muscle, blood flow to other organs was simultaneously assessed. In both groups of animals, sciatic nerve was sectioned on 1 side (i.e., denervated;
solid bars) and left intact on contralateral leg (i.e., innervated; open bars). Values are means + SE; n = 7 rats/group. *P < 0.05 vs. time-matched control values.
